Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
RELIEF THERAPEUTICS Holding ( (CH:RLF) ) just unveiled an announcement.
Relief Therapeutics has announced the agenda for its 2025 Annual General Meeting, scheduled for June 12, 2025, in Geneva. The agenda includes the approval of the 2024 annual report, financial statements, and compensation amounts for the board and executive committee, among other items. This meeting is crucial for stakeholders as it outlines the company’s governance and financial strategies for the coming year, which could impact its market positioning and operational focus.
More about RELIEF THERAPEUTICS Holding
Relief Therapeutics Holding SA is a commercial-stage biopharmaceutical company based in Geneva, Switzerland. The company focuses on developing innovative treatment options for rare and debilitating diseases, with expertise in drug delivery systems and drug repurposing. Relief has a clinical pipeline targeting rare dermatological, metabolic, and respiratory conditions, and has successfully brought several products to market through licensing and distribution partnerships. It is listed on the SIX Swiss Exchange and quoted in the U.S. on OTCQB.
Average Trading Volume: 23,234
Current Market Cap: CHF26.47M
Find detailed analytics on RLF stock on TipRanks’ Stock Analysis page.